Regeneron Pharmaceuticals Q3 2025 Financial Results

Regeneron Pharmaceuticals reported its third quarter 2025 financial results, showing a 1% increase in total revenues to $3.75 billion compared to the same period in 2024. Key highlights include a 27% increase in global net sales of Dupixent to $4.86 billion, a 10% rise in U.S. net sales of EYLEA HD to $431 million, and a 28% decline in total U.S. net sales of EYLEA HD and EYLEA to $1.11 billion. The company also reported GAAP EPS of $13.62 and non-GAAP EPS of $11.83. Regeneron made significant progress in its pipeline, with FDA approvals for Libtayo in high-risk adjuvant cutaneous squamous cell carcinoma and positive Phase 3 results in several other trials. The company also returned over $3 billion to shareholders through share repurchases and dividends.